Tyler Shultz, the former Theranos research engineer who famously blew the whistle on the collapsing biotech startup, has alleged that convicted fraudster and founder Elizabeth Holmes deliberately misled filmmaker Nathan Fielder regarding the company's proprietary technology during a pivotal segment of his new documentary, “You Can See Everything.”

Speaking to CBS Mornings, Shultz asserted that Holmes intentionally deceived Fielder by presenting what she claimed was a functional Theranos blood-testing apparatus. According to Shultz, that machinery bore no resemblance to the equipment he operated daily.

“My problem was, that was not the device that I worked with 12 hours a day,” Shultz stated, emphasizing that the machine displayed was neither the apparatus concealed from regulators nor the one that repeatedly failed quality control standards.

Shultz argued that Holmes steered Fielder down an entirely fabricated path, showing him an experimental prototype that was never finished nor deployed on actual patients. Furthermore, Shultz noted that Holmes appeared almost unrecognizable in the production, lacking the boardroom swagger of her tenure as CEO and instead resembling a broken individual.

He expressed zero astonishment that Holmes—currently serving an 11-year prison sentence following her fraud conviction—maintains her innocence, claiming she remains entangled in a persistent web of falsehoods.

Shultz Contends “You Can See Everything” Is Artistic Fiction

In a critical review published for the science publication STAT, Shultz argued that the project defies classification as a traditional documentary, warning that treating it as objective journalism is dangerous. Instead, he categorized the film as an artistic endeavor engineered to manufacture ambiguity. Shultz posited that Fielder is either an incompetent documentarian duped by his subject or a brilliant artist who deliberately permitted Holmes to hoodwink viewers.

Shultz also dissected other polarizing moments in the feature, including a scene where Fielder screens the classic Abbott and Costello routine “Who’s on First?” for Holmes. While Holmes acts bewildered, Shultz suggested she comprehended the humor perfectly and feigned ignorance to cultivate an aura of peculiar literal-mindedness.

Additional discrepancies were highlighted regarding Holmes's travel to prison, contrasting the film's depiction of a San Diego drive with her partner Billy Evans's account of a private jet financed by an acquaintance. Shultz accused Holmes of launching Theranos out of a desire for celebrity status, conceding she may have suffered through abusive dynamics yet maintaining those experiences do not excuse her unlawful conduct.

Perspectives From Insiders And Box Office Success

Reflecting on LinkedIn, Shultz admitted to mixed feelings regarding the film's release but expressed hope that audiences would finally grasp the reality of Holmes's persona. John Carreyrou, the investigative journalist whose Wall Street Journal exposés dismantled Theranos, praised the film on social media as a cinematic triumph. Carreyrou noted that if Holmes anticipated a sympathetic portrayal, she committed a monumental error, reiterating that she ruthlessly orchestrated a breathtaking fraud.

The nearly three-hour feature chronicling Fielder's time with Holmes and Evans prior to her incarceration debuted to staggering success, grossing $15 million in limited release across fewer than 1,000 locations—the highest-grossing documentary opening in twenty years. Distributor A24 reported over 2,000 sold-out screenings.

The cinematic resurgence has reignited public fascination with the scandal, driving a 200% surge in viewership for the Hulu miniseries “The Dropout” starring Amanda Seyfried. Concurrently, sales and audio streams for Carreyrou’s bestselling book “Bad Blood” spiked exponentially across platforms like Spotify.

Once boasting a net worth of $4.5 billion at Theranos's peak valuation of $9 billion, Holmes's financial standing was entirely wiped out by Forbes in 2016 following intense scrutiny over the efficacy of the company's blood-testing technology.